化合物ABT-737 T2099

Product Introduction
Bioactivity


英文名: ABT-737

描述: ABT737 是 BH3 模拟物，是Bcl-2、Bcl-xL 和Bcl-w 抑制剂，EC50分别为 30.3 nM、78.7 nM 和 197.8 nM。它诱导自噬，有研究急性髓系白血病的潜力。它还诱导 BCL-2/BAX 复合物的破坏和 BAK 依赖性。

细胞实验: Cells were seeded into 96-well plates (5 × 10^3 cells/well) and cultured for 12 h at 37 °C, as described above. Then, the medium was replaced with RPMI 1640 containing various concentrations of ATO (1, 2, 4 and 8 nM), ABT-737 (2.5, 5, 10 and 20 μM) or combinations of ATO and ABT-737, and cells were cultured for a further for 24, 48 or 72 h at 37 °C. Cells cultured in RPMI 1640 containing an equal volume of 0.01 M phosphate-buffered saline (PBS, pH 7.4; vehicle) served as controls. Cell viability was measured using Cell Counting Kit-8, according to the manufacturer's instructions. The cell proliferation rate was calculated according to the formula: experimental optical density (OD) value/control OD value × 100%. Experiments were repeated in triplicate [2].

激酶实验: To determine the binding affinity of GST-BCL-2 family proteins to the FITCconjugated BH3 domain of BIM, FPAs were performed as described. Briefly, 100 nM of GST-BCL-2 family fusion proteins were incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-BIM BH3 peptide was added. Fluorescence polarization was measured using a Detection System after 10 min using the 96-well black plate. IC50s were determined [1].

动物实验: Mice were housed under standard conditions and had free access to water and food, under a 12-h light/12-h dark cycle in a room maintained at 18 – 22 °C and 50 – 65% humidity. SGC7901 cells (5 × 10^6) were subcutaneously inoculated into the right flank of BALB/c mice (H-2b). Tumour volume was measured using callipers and estimated according to the formula: π ? 6 × a2 × b, where a was the short axis, and b was the long axis. After 10 days, when the tumours had reached about 0.2 cm in diameter, the mice were randomly assigned to four groups (n = 8 per group), using a randomization schedule generated by the SAS software package. The groups were: control; ABT-737; ATO; ABT737 + ATO. They received, respectively: vehicle (1% DMSO, 99% 0.01 M PBS; pH 7.4); ABT-737 (50 mg/kg); ATO (2.5 mg/kg); ABT737 (50 mg/kg) + ATO (2.5 mg/kg) intraperitoneally (i.p.) every 2 days. Drugs were dissolved in the vehicle solution. To standardize the experiments, each mouse received a similar volume of solution. After 15 days, the mice were euthanized and the solid SGC-7901 tumours were harvested, fixed with 4% paraformaldehyde, frozen in optimal cutting temperature compound and stored at –80 °C [2].

体外活性: ABT-737 induced the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. In cells with phosphorylated BCL-2 or increased MCL-1, ABT-737 was inactive. Inhibition of BCL-2 phosphorylation and reduction of MCL-1 expression restored sensitivity to ABT-737 [1]. ABT-737 inhibited proliferation and induced apoptosis in SGC-7901 and MGC-803 cells in concentration- and time-dependent manners. ABT-737 disturbed the binding of B cell lymphoma (Bcl)-2 homologous antagonist killer and Bcl-extra large [2]. ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells [3].

体内活性: ABT-737 and ATO significantly suppressed SGC-7901 xenograft growth, synergistically inhibited tumour growth and induced apoptosis in vivo [2]. H146 tumours were treated with a single dose of ABT-737. A significant increase in caspase-3-positive cells was noted as early as 2 h after treatment, with a 12-fold increase achieved within 16 h. Examination of liver, heart, and intestine revealed no increase in caspase-3 activation in these normal tissues [3]. Treatment with either ABT-737 (100 mg/kg/day) was initiated on the day following inoculation. On day 21 post-treatment, the mean tumor volume, weight, and serum level of sIL-2Ra were significantly lower than those of vehicle-treated mice [4].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
5% DMSO+95% Saline : 4.65 mg/mL (5.72 mM, suspension)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 50 mg/mL (61.47 mM)


关键字: Mitophagy | inhibit | mimetic | HCT116 | Apoptosis | BIM | ABT 737 | BH3 | Autophagy | AML | HL-60 | Bcl-2 Family | Mitochondrial Autophagy | BCL-2/BAX | ABT737 | Inhibitor | ABT-737

相关产品: Polydatin | Carbamazepine | Vorinostat | U0126 | Valproic acid sodium salt | Dexamethasone | Doxorubicin hydrochloride | Valproic Acid | Simvastatin | Brefeldin A

相关库: Anti-Aging Compound Library | ReFRAME Related Library | Anti-Cancer Compound Library | Human Metabolite Library | Inhibitor Library | Anti-Cancer Active Compound Library | Hematonosis Compound Library | Cuproptosis Compound Library | Autophagy Compound Library | NO PAINS Compound Library

化合物ABT-737 T2099信息由TargetMol中国为您提供，如您想了解更多关于化合物ABT-737 T2099报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途